ECG Core Lab

Richmond Pharmacology’s Core ECG Laboratory was established in 2004 to provide centralized digital and manual ECG data analysis for Richmond Pharmacology’s in house TQT trials, in addition to ECG reading, analysis and reporting for clinical trials conducted at other centres.

As a standard Richmond Pharmacology use FDA compliant Digital 12-Lead ECG and Digital 12-Lead Holter devices for collection, transmission and processing of digital ECG and Holter recordings for TQT studies.

Each bedside has a GE MAC 1200, 12-lead ECG machine connected to the MUSE® Server allowing for storage of thousands of digital ECG’s. These digitized ECG's are available to our cardiological sciences team as required for subsequent digitized reading, analysis and reporting. The system is FDA 21 CFR Part 11 compliant with secure authorized user access and password protection to allow access to users for their required access levels only. A detailed audit trail is available and includes the username, date and time of access of any individual using the system and what addition or change they made to the database.

Prior to commencement of a study involving Richmond Pharmacology, all digital 12-Lead ECG machines used for the project are configured to ensure that every ECG data file contains the exact and correct information in FDA compliant format (HL7) as per ICH E14. The configuration of each of Richmond Pharmacology’s ECG machines used in our in house or external TQT study undergoes a vigorous validation process, including acquisition and transfer of test ECGs from the machine’s simulator. To further standardise the process, the same machine is always used for the same subject throughout the study. The standard configuration and validation process is fully documented and available to clients upon request.

The digital 12-Lead Holter devices used by Richmond Pharmacology are designed to be used for FDA compliant arrhythmia analysis. The data obtained from these digitised 12-Lead Holter devices ensure Richmond Pharmacology’s core lab can report on ventricular and supraventricular arrhythmias, and ischemia parameters in addition to quantifying heart rates and providing qualitative reporting of cardiac rhythm information.

Our experts

Professor Camm - Professor of Cardiology

Professor Camm's major speciality is cardiac arrhythmias but he is also much involved in clinical cardiac electrophysiology, cardiac pacemakers and risk stratification in post myocardial infarction, heart failure and cardiomyopathy drugs.

Read biography

Dr Jorg Taubel - MD FFPM
(CEO)

Dr Jorg Taubel is a medical practitioner and CEO of Richmond Pharmacology which he co-founded in 2001. He has worked in clinical pharmacology for over 24 years and during that time he has conducted more than 400 early phase studies..

Read biography

Experience

  • Track record of 100% success in conducting QTC studies
  • Many of our QTc studies have been published.

Set-up

  • State of the art methods and equipment
  • Tried and tested processing for ECG adjudication and data analysis

We are

  • Excellence in ECG acquisition allows meaningful ECG analysis
  • Option to include a non-pharmacological method of proving assay sensitivity

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more

Dr Jorg Taubel, CEO of Richmond Pharmacology, features on the PM Live website, discussing clincial trials and COVID-19

August 11, 2020
Dr Jorg Taubel discusses some of the steps taken at Richmond Pharmacology to ensure clinical trials can continue to operate at a high standard throughout the COVID-19 pandemic.
Read more